SCHEMBL5574715

SCHEMBL5574715

CC(C)(C)OC(=O)NC1=NC(=O)CN1C(=O)OCc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.43
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
GAA P10253 1/20 0.42
MAPK1 P28482 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CTSL P07711 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
PPARA Q07869 1/20 0.40
TOP2A P11388 1/20 0.39
TOP2B Q02880 1/20 0.39
MAPT P10636 1/20 0.39
CTSS P25774 1/20 0.39
KLK7 P49862 1/20 0.38
KLK5 Q9Y337 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA7 P43166 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5571305 0.85 RAB9A (0.46) NPC1RAB9AGAAMAPK1SMN1; SMN2
SCHEMBL5573329 0.80 SMN1; SMN2 (0.47) NPC1RAB9AGAAMAPK1SMN1; SMN2
SCHEMBL5573744 0.77 NPC1 (0.52) NPC1RAB9AGAAMAPK1SMN1; SMN2
SCHEMBL5573787 0.76 SMN1; SMN2 (0.42) NPC1RAB9AGAAMAPK1SMN1; SMN2
SCHEMBL5573770 0.75 NPC1 (0.42) NPC1RAB9AGAAMAPK1SMN1; SMN2
SCHEMBL6620619 0.74 KMT2A (0.47) NPC1RAB9ASMN1; SMN2CTSLL3MBTL1
SCHEMBL6620628 0.74 KMT2A (0.47) NPC1RAB9ASMN1; SMN2CTSLL3MBTL1
SCHEMBL5571307 0.74 MEN1 (0.44) NPC1RAB9AGAAMAPK1SMN1; SMN2
SCHEMBL5573293 0.74 NPC1 (0.51) NPC1RAB9AGAAMAPK1SMN1; SMN2
SCHEMBL3375815 0.73 P2RX7 (0.41) NPC1RAB9AGAAMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7268231-B2 1,5-Naphthyridine azolinone HOFFMANN-LA ROCHE INC. (US) 2007-09-11 US disclosed
EP-1805174-A1 1,5-NAPHTHYRIDINE AZOLIDINONES HAVING CDK1 ANTIPROLIFERATIVE ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2007-07-11 EP disclosed
WO-2006040052-A1 1,5-NAPHTHYRIDINE AZOLIDINONES HAVING CDK1 ANTIPROLIFERATIVE ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2006-04-20 WO disclosed
US-20060084673-A1 1,5-naphthyridine azolinone LIU JIN-JUN 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084673-A1 1,5-naphthyridine azolinone CDK1, CDK15, CDK14 SYK 3002/4885NPC1 3308/4885RAB9A 3599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.